Inhibition of glucose-stimulated insulin release in the perfused rat pancreas by parathyroid secretory protein-I (chromogranin-A)

Endocrinology. 1989 Mar;124(3):1235-8. doi: 10.1210/endo-124-3-1235.

Abstract

The effect of graded doses (10(-10)-10(8) M) of highly purified bovine parathyroid secretory protein-I (SP-I; chromogranin-A) or synthetic porcine pancreastatin on glucose-stimulated insulin release in the perfused rat pancreas was examined. SP-I (10(-9) M) inhibited the first phase of glucose-stimulated insulin release, and 10(-8) M SP-I inhibited both the first and second phases of glucose-stimulated insulin release; 10(-10) M SP-I was inactive. In comparison, pancreastatin at 10(-10) M inhibited the first phase of insulin release, and at 10(-9) and 10(-8) M, pancreastatin inhibited both phases of insulin release. The inhibition by SP-I was achieved at concentrations that normally exist in the general circulation of man. These and other data suggest that circulating SP-I plays a physiological role in the regulation of insulin secretion.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Chromogranin A
  • Chromogranins / administration & dosage
  • Chromogranins / pharmacology*
  • Dose-Response Relationship, Drug
  • Glucose / pharmacology*
  • Insulin / metabolism*
  • Insulin Secretion
  • Male
  • Nerve Tissue Proteins / pharmacology*
  • Pancreas / drug effects
  • Pancreas / metabolism*
  • Pancreatic Hormones / administration & dosage
  • Pancreatic Hormones / pharmacology
  • Perfusion
  • Rats
  • Rats, Inbred Strains

Substances

  • Chromogranin A
  • Chromogranins
  • Insulin
  • Nerve Tissue Proteins
  • Pancreatic Hormones
  • chromogranin A, rat
  • pancreastatin
  • Glucose